Shenzhen Zhonglian Pharmaceutical Co., Ltd. was founded in 1988. It is mainly engaged in the research, production, sale and after sale service of the drugs in the endocrine system. It is a wholly owned subsidiary of Shenzhen Zhonglian Guang Shen Pharmaceutical (Group) Limited by Share Ltd. Shenzhen Zhonglian Pharmaceutical Co., Ltd. was founded 30 years, always adhere to the "pragmatic, enterprising, excellence" spirit of enterprise and the "scientific, rigorous, standardized" business policy and in the field of endocrine treatment of diabetes, thyroid disease medication direction, to "Tang Jun meidicom (Metformin Hydrochloride Tablets), plus balance (Levothyroxine Sodium Tablets & reg)," Jiatai R (Potassium Chloride Sustained-release Tablets) and other renowned national well-known brand drugs, has repeatedly been rated as Shenzhen city "civilized enterprises", "the contract and trustworthy enterprise", "labor management trustworthy enterprise", "high-tech enterprises in Guangdong province" and "advanced enterprise in quality and efficiency".
Zhonglian pharmaceutical in 2015 obtained the new version of raw materials and preparations GMP double certification, with first-class production equipment and fully meet the requirements of the GMP standard factory. As the rapid development of enterprises, better adapt to the pharmaceutical industry, in the loving care of Shenzhen city and Pingshan district government with strong support, Zhonglian pharmaceutical factory projects located in Pingshan bio Pharmaceutical Industrial Park, development opportunities to take off again. The completion of the new plant will meet the latest industry standard of pharmaceutical GMP at home and abroad, and design and build a modern enterprise that integrates intelligence, environmental protection, efficient automation and specialized R & D. The construction area of the new plant is more than 5 million square meters, and 2 billion 800 million tablets of oral solid preparation for chemical drugs are produced in the year. According to the requirements in February 2019 to achieve the main project completion acceptance, plans to achieve early 2020 fully completed and put into production, and strive to build a national essential drugs will be Tang Jun meidikang, R, R, Heng Jiatai well-known pharmaceutical enterprise benchmarking.